Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 6/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.34 |
| ▸ | TDO2 | P48775 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | CD38 | P28907 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775748 | 0.88 | MAPKAPK2 (0.45) | EGFRPTGS2MAPTMAPKAPK2ABCB1 | |
| SCHEMBL4776048 | 0.87 | NPC1 (0.41) | EGFRERBB2PTGS2MAPTMAPKAPK2 | |
| SCHEMBL4769765 | 0.85 | SLC2A1 (0.42) | EGFRERBB2PTGS2MAPKAPK2ABCB1 | |
| SCHEMBL4767004 | 0.85 | ABCG2 (0.43) | EGFRLMNAMAPTHPGDABCB1 | |
| SCHEMBL4777976 | 0.84 | FADS1 (0.43) | EGFRERBB2TDO2PTGS2SYK | |
| SCHEMBL4766924 | 0.80 | ABCB1 (0.39) | LMNAABCB1ABCG2 | |
| SCHEMBL4769773 | 0.80 | MAP2K1 (0.44) | LMNAMAPTMAPKAPK2ABCB1ABCG2 | |
| SCHEMBL4767045 | 0.78 | MAP2K1 (0.46) | EGFRERBB2ABCB1ABCG2 | |
| SCHEMBL4774191 | 0.75 | EGFR (0.55) | EGFRERBB2 | |
| SCHEMBL4768795 | 0.71 | CYP11B2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432279-B2 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1881981-A1 | 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | Wyeth (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124944-A1 | 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CNKSR1, DTYMK | KCNQ3 4231/4885KCNQ2 4114/4885IDO1 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.